Evoke Pharma Inc. (EVOK) Sees Unusually-High Trading Volume
Evoke Pharma Inc. (NASDAQ:EVOK) saw strong trading volume on Tuesday . 111,441 shares changed hands during mid-day trading, an increase of 82% from the previous session’s volume of 61,137 shares.The stock last traded at $6.85 and had previously closed at $7.18.
A number of research analysts have recently weighed in on the company. Zacks Investment Research cut Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Monday, May 16th. FBR & Co restated a “buy” rating on shares of Evoke Pharma in a research report on Saturday, May 14th. Rodman & Renshaw restated a “buy” rating on shares of Evoke Pharma in a research report on Thursday, May 12th. Brean Capital restated a “buy” rating on shares of Evoke Pharma in a research report on Thursday, May 12th. Finally, Northland Securities assumed coverage on Evoke Pharma in a research report on Wednesday, March 16th. They issued an “outperform” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $17.47.
The company’s market capitalization is $51.68 million. The company has a 50 day moving average price of $5.91 and a 200-day moving average price of $4.50.
Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.04. On average, equities analysts expect that Evoke Pharma Inc. will post ($1.36) earnings per share for the current year.
In other news, major shareholder Parters Vii L. P. Domain sold 51,004 shares of the company’s stock in a transaction on Friday, April 8th. The stock was sold at an average price of $5.28, for a total value of $269,301.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the company’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $4.70, for a total value of $1,617,364.00. The disclosure for this sale can be found here.
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.